Sign in

You're signed outSign in or to get full access.

Karla J. Peterson

Vice President, Acquisitions and Development at UNIVERSAL HEALTH REALTY INCOME TRUST
Executive

About Karla J. Peterson

Karla J. Peterson, age 65, serves as Vice President, Acquisitions and Development at Universal Health Realty Income Trust (UHT) since August 2022; previously she was Managing Director of Acquisitions & Asset Management at White Oak Healthcare MOB REIT (2020–2022) and Executive Vice President at A10 Capital (2017–2020) . UHT’s incentive framework tying equity awards to three-year average total shareholder return (TSR) relative to a peer set resulted in minimum-level grants for 2024 as UHT’s 2021–2023 TSR was -7.2% versus NAREIT 2.7% and peer group 3.6% . Company pay-versus-performance disclosures show 2024 FFO of $47.9 million and net income of $19.2 million, contextualizing performance conditions used in pay design .

Past Roles

OrganizationRoleYearsStrategic Impact
White Oak Healthcare MOB REIT, LLCManaging Director, Acquisitions & Asset Management2020–2022Led acquisitions and asset oversight in healthcare MOBs
A10 CapitalExecutive Vice President2017–2020Senior leadership role at a commercial finance platform

External Roles

No external directorships or board roles disclosed for Peterson in UHT filings.

Fixed Compensation

UHT does not pay base salaries or routine cash bonuses to executive officers; compensation is primarily long-term, equity-based. The summary compensation for Peterson reflects no salary or cash bonus in 2022–2024, with dividends on unvested restricted stock accrued and paid at vesting.

Metric202220232024
Base Salary ($)
Cash Bonus ($)
All Other Compensation ($)$1,599 $5,786 $8,494
Total ($)$56,622 $62,992 $67,995

Notes: All Other Compensation reflects dividends accrued on unvested restricted stock; paid only upon vest on shares that ultimately vest .

Performance Compensation

Equity awards are performance-based restricted stock linked to UHT’s three-year average TSR versus peers/NAREIT, with vesting two years post grant; dividends on unvested shares accrue and pay at vest .

YearInstrumentGrant DateShares GrantedGrant Date Fair ValuePerformance MetricOutcome/PayoutVesting
2022RS (performance-based)Sep 2022— (value shown) $55,023 TSR vs peer/NAREIT (framework) Vested 1,122 shares in 2024 Sep 2024 (2-year)
2023RS (performance-based)Jun 2023— (value shown) $57,206 TSR vs peer/NAREIT (framework) Minimum grant level for 2024 cycle; 2023 award scheduled Jun 2025: 1,180 shares
2024RS (performance-based)Jun 5, 20241,556 $59,501 3-year avg TSR 2021–2023 vs peers/NAREIT Awards at minimum level due to TSR underperformance Jun 2026 (2-year)
2025RS (performance-based)Jun 11, 20251,540 TSR framework continues Granted per annual LTI process Jun 2027 (2-year)

Additional design details:

  • Vesting: Restricted shares vest on the second anniversary of grant; dividends accrue and pay at vest on shares that ultimately vest .
  • Metric emphasis: TSR is the chief determinant of award levels; FFO and adjusted net income are cited as important measures correlating to TSR but not directly used to set award ranges .

Equity Ownership & Alignment

ItemValue
Beneficial Ownership (Mar 31, 2025)3,858 shares; less than 1% of outstanding
Unvested Awards at 12/31/20241,180 shares vesting June 2025; 1,556 shares vesting June 2026
Market Value of Unvested (12/31/2024)$43,908 for 1,180; $57,899 for 1,556 (based on $37.21/share)
Shares Acquired on Vesting (2024)1,122 shares; value realized $50,086
Options OutstandingNone; no options or DERs outstanding
Pledging/HedgingNo shares pledged by Trustees/executives; hedging transactions prohibited by policy

Ownership guidelines/compliance not disclosed. Equity plan remaining authorization was 92,362 shares as of 12/31/2024 .

Employment Terms

  • Role and start date: Vice President, Acquisitions & Development since August 2022 .
  • Severance/Change-of-control: No committed severance or change-in-control payments for NEOs; Board/Compensation Committee may, at discretion, approve immediate vesting of restricted stock .
  • Clawback: Effective October 2, 2023, UHT adopted an NYSE/SEC-aligned clawback policy covering incentive compensation upon required accounting restatement .
  • Hedging: Hedging in Trust securities is prohibited for employees and Trustees .
  • Contract specifics (non-compete, non-solicit, auto-renewal, garden leave): Not disclosed in filings reviewed.

Compensation Structure Analysis

  • Cash vs equity mix: All at-risk equity; no base or annual cash bonus paid by UHT to Peterson in 2022–2024, consistent with program design .
  • Metric rigor: 2024 awards at minimum due to 3-year TSR underperformance versus peer/NAREIT averages (-7.2% vs 3.6% and 2.7%), signaling a direct pay-for-performance linkage .
  • Option usage: UHT utilizes restricted stock rather than options; none outstanding for Peterson, reducing repricing risk .
  • Discretionary bonuses: None granted in 2022–2024 to NEOs .
  • Advisory model context: Officers are employees of UHS’s subsidiary; UHT pays a fixed advisory fee and grants UHT equity directly to NEOs .

Performance & Track Record

  • Company TSR (cumulative value of $100 investment): UHT’s 5-year TSR track and peer group TSR are disclosed; 2024 value was $41.75 for UHT vs $135.35 for the peer group, evidencing underperformance over the period .
  • Earnings/FFO: Net income $19.2 million and FFO $47.9 million for 2024 (non-GAAP per NAREIT standards), with reconciliation provided .
  • Say-on-pay: Shareholder support increased following enhanced disclosures; historical approval ~93–94%, and 2025 votes in favor were 9,240,529 .

Board Governance (Context)

  • Compensation Committee: Independent members oversee equity plan and awards; NEO grants are based on peer benchmarking and performance assessments .
  • 2025 Annual Meeting outcomes: Trustees elected; say-on-pay approved; KPMG ratified .

Investment Implications

  • Alignment: Peterson’s compensation is fully equity-based with vesting tied to long-term TSR, aligning incentives with shareholder returns; awards were reduced to minimum when TSR underperformed peers/NAREIT .
  • Retention and supply overhang: Upcoming vesting tranches of 1,180 (Jun 2025), 1,556 (Jun 2026), and 1,540 (Jun 2027) could create episodic selling pressure around vest dates; absence of options lowers leverage-driven sale risk .
  • Governance risk: No severance or change-of-control cash protections; clawback and hedging prohibitions strengthen governance; no pledging reported among executives .
  • Performance watch: UHT’s longer-term TSR underperformance and reliance on TSR-driven grants suggest award sensitivity to sustained improvements in FFO and net income that correlate with TSR, impacting future equity grant levels and vest outcomes .